復星醫藥(02196.HK)擬向天津金耀轉讓天津藥業合計25.0011%股權
格隆匯8月23日丨復星醫藥(02196.HK)公吿,公司擬向天津金耀轉讓所持有的天津藥業合計25.0011%的股權,本次轉讓價款總額為人民幣14.3億元;根據約定,本次轉讓預計將分三期付款和交割。
天津藥業成立於1988年7月,註冊地天津市河東區,法定代表人為郭珉。天津藥業的經營範圍為化學原料藥及中間體、製劑、中成藥、中藥材、化工原料、葫蘆巴膠的製造、加工和銷售及技術服務、諮詢、研發、轉讓;承包中外合資經營、合作生產企業;勞動服務;開展對外經濟技術合作業務;自有房屋出租;限分支機構經營:保健食品製造、加工、銷售(以上範圍內國家有專營專項規定的按規定辦理)(依法須經批准的項目,經相關部門批准後方可開展經營活動)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.